Yescarta, Breyanzi Offer Practice-Changing Options For Second-Line LBCL
Both CAR-Ts Offer Survival Gains, With Longer Data For Kite’s Product
After years with chemo and stem cell transplant as the only second-line option, CAR-T therapy offers a more effective solution • Source: Alamy 
